Mass General Brigham Innovation Discovery Grants (IDG)
IDG 2021: Cell and Gene Therapy
The IDG focus in 2021 is on Gene and Cell Therapy. For purposes of this RFA, Gene Therapy is defined as a subset of genomic medicine that includes all the therapeutic modalities that treat a genetic disorder by influencing the structure, expression or inhibition of a gene and the consequent gene product(s).
Key Dates and Information:
- Pre-proposals are due January 11, 2021
- Full proposals will be invited by February 22, 2021
- Full proposals will be due March 30, 2021
- Awards will be announced at the World Medical Innovation Forum in May, 2021
- Applicants may request up to $100,000 total cost (inclusive of 15% indirect costs)
- 12-month project periods are anticipated
To be eligible for an IDG award, lead applicants must have PI privileges at an institution within Mass General Brigham, or full-time employee status at an institution within the Mass General Brigham system. IP must be assigned to a Mass General Brigham entity.
IP must be assigned to a Mass General Brigham entity and awards will be governed by the Mass General Brigham Intellectual Property Policy.
Do not include unprotected proprietary information in your application. External pharma and device companies will be actively involved in the review process. Questions related to intellectual property and confidentiality should be directed to your Innovation Licensing Manager at 857-307-2400 https://innovation.partners.org/our-team.
Questions related to IDG grants policies or procedures should be directed to Lesley Watts, Administrative Director, at email@example.com / 857-307-2440. Questions related to the business opportunity should be directed to your Partners Innovation Licensing Manager or Market Sector Leader at 857-307-2400.